如何看待全球风险偏好的降温？

Group 1: Market Overview - The market experienced pressure with a total decline of 5.13% across all A-shares during the week of November 17-21, with the Shanghai 50 and CSI Dividend Index showing narrower declines compared to the severe setbacks in the ChiNext Index and micro-cap stocks [2][10] - All 31 Shenwan industries recorded losses, with banking, media, and food and beverage sectors experiencing smaller declines, while basic chemicals, comprehensive, and electric equipment sectors led the losses [10] Group 2: Market Observations - The stock-bond yield spread increased to 0.8%, which is below the +1 standard deviation, indicating a decrease in valuation differentiation by 13.3% [22] - Market sentiment adjusted with a decrease of 10.7% in the sentiment index to 49.6, while industry rotation intensity rose above the warning level of 40 [23] - The trading volume decreased week-on-week, with leading sectors in bullish stocks being banking, agriculture, forestry, animal husbandry, and defense industries, while steel, basic chemicals, and electric equipment may present alpha opportunities [30] Group 3: Industry Highlights - The launch of the multimodal AI assistant "Lingguang" achieved over one million downloads within four days, indicating strong market interest in AI applications [49] - China International Capital Corporation (CICC) plans to absorb and merge with Dongxing Securities and Xinda Securities, signaling a shift in the brokerage industry landscape [50] - The 2025 Quantum Technology and Industry Conference held in Hefei showcased significant advancements in quantum technology, suggesting potential investment opportunities in this sector [51] Group 4: Industry Allocation - A phase of rebalancing is anticipated in the market, with previously lagging sectors such as dividends and domestic demand expected to offer better value in the short term [53] - Long-term outlook remains positive for technology growth sectors including TMT, Hang Seng Technology, energy storage, satellite connectivity, commercial aerospace, and innovative pharmaceuticals [53]